Publications by authors named "Nicholas McAndrew"

Claim this Profile
R
Role of immunotherapy in early breast cancer: past, present, and future.
Karissa Britten, Aditya Bardia, Nicholas McAndrew

Target Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surgical outcomes following neoadjuvant chemotherapy with and without immunotherapy in patients with triple-negative breast cancer.
Anouchka Coste Holt, Courtney A Smith, Maurice J Berkowitz, Jennifer L Baker, Nicholas P McAndrew

Discov Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rectal Cancer Survival for Residual Carcinoma In Situ Versus Pathologic Complete Response After Neoadjuvant Therapy.
Nathan M Kohrman, Jordan R Wlodarczyk, Li Ding, Nicholas P McAndrew, Sandra D Algaze

Dis Colon Rectum· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ribociclib plus Endocrine Therapy in Early Breast Cancer.
Dennis Slamon, Oleg Lipatov, Zbigniew Nowecki, Nicholas McAndrew, Bozena Kukielka-Budny

N Engl J Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New approaches for human epidermal growth factor receptor 2-low and human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
Karissa Britten, Nicholas McAndrew

Curr Opin Obstet Gynecol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor.
Jian Zhang, Nicholas P McAndrew, Xiaojia Wang, Yiqun Du, Brian DiCarlo

Breast Cancer Res· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic Therapy for Early- and Late-Stage, Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer.
Nicholas P McAndrew, Sara A Hurvitz

Hematol Oncol Clin North Am· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer.
Igor Makhlin, Nicholas P McAndrew, E Paul Wileyto, Amy S Clark, Robin Holmes

NPJ Breast Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Review on the Management of Hormone Receptor-Positive Metastatic Breast Cancer.
Nicholas P McAndrew, Richard S Finn

JCO Oncol Pract· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapy regimen choice and patient outcomes in early-stage triple-negative breast cancer: a retrospective analysis.
Sanaz N Ghafouri, Rebecca W Nayeri, Nicholas P McAndrew, Sara A Hurvitz

Ther Adv Med Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updates on targeting human epidermal growth factor receptor 2-positive breast cancer: what's to know in 2021.
Nicholas P McAndrew

Curr Opin Obstet Gynecol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A careful reassessment of anthracycline use in curable breast cancer.
Sara Alsterlind Hurvitz, Nicholas P McAndrew, Aditya Bardia, Michael F Press, Mark Pegram

NPJ Breast Cancer· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of systemic inflammation on relapse in early breast cancer.
Nicholas P McAndrew, Lisa Bottalico, Clementina Mesaros, Ian A Blair, Patricia Y Tsao

NPJ Breast Cancer· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of ER positive metastatic breast cancer.
Nicholas P McAndrew, Richard S Finn

Semin Oncol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early treatment-related neutropenia predicts response to palbociclib.
Nicholas P McAndrew, Mark A Dickson, Amy S Clark, Andrea B Troxel, Mark H O'Hara

Br J Cancer· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in Targeted Therapies for Triple-Negative Breast Cancer.
Kelly E McCann, Sara A Hurvitz, Nicholas McAndrew

Drugs· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer.
Amy S Clark, Nicholas P McAndrew, Andrea Troxel, Michael Feldman, Priti Lal

Clin Cancer Res· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Chemotherapy Considerations in Triple-Negative Breast Cancer.
Nicholas McAndrew, Angela DeMichele

J Target Ther Cancer· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges in the clinical utility of the serum test for HER2 ECD.
Lian Lam, Nicholas McAndrew, Marla Yee, Ting Fu, Julia C Tchou

Biochim Biophys Acta· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumors at the aortoiliac/inferior vena cava bifurcation: preoperative, anesthetic, and intraoperative considerations.
James R Ouellette, David V Cossman, Karen S Sibert, Nicholas P Mcandrew, Allan W Silberman

Am Surg· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis